MFDS — authorised 26 June 1997
- Marketing authorisation holder: MCNEIL
- Status: likely_approved
🇰🇷 Imodium Multi-Symptom Relief in South Korea
MFDS authorised Imodium Multi-Symptom Relief on 26 June 1997
Marketing authorisation
Imodium Multi-Symptom Relief in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Dermatology approved in South Korea
Frequently asked questions
Is Imodium Multi-Symptom Relief approved in South Korea?
Yes. MFDS authorised it on 26 June 1997.
Who is the marketing authorisation holder for Imodium Multi-Symptom Relief in South Korea?
MCNEIL holds the South Korean marketing authorisation.